Bristows

Latest from Bristows - Page 3

21.02.2024

Our EU and UK competition law expert, Sean-Paul Brankin, has been quoted in PaRR’s article on 21st February 2024, ‘OpenAI/Microsoft: EU, UK reviews may have difficulty establishing jurisdiction – analysis’.
The piece summarises ‘whether Microsoft’s investment in the developer of ChatGPT might be reviewable under the EU Merger Regulation, following the UK regulator’s

29.01.2024

Extending the transitional periods for implementation
A considerable number of in vitro diagnostic medical devices (IVDs) currently on the European market do not yet comply with the In Vitro Diagnostic Medical Device Regulation 2017/746 (IVDR). The deadlines for IVDs to comply with the new requirements were looming and causing significant concern for the industry, the pharmaceutical sector

29.01.2024

The promotions of Charlie French and Naomi Hazenberg (effective 1 May 2024) are a reflection of Bristows’ commitment to its unparalleled, full service offering across all IP-rich sectors and enhances the firm’s unique expertise in Life Sciences and Technology.
Charlie French
With a background in biochemistry and a deep understanding of the life

06.12.2023

J.C. Bamford Excavators Limited v Manitou UK Limited (1) and Manitou BF SA (2) [2023] EWCA Civ 840
This article first appeared in the Intellectual Property Forum journal, published by Intellectual Property Society of Australia and New Zealand. Lucie Fortune, “Current Developments – Europe: United Kingdom: Court of Appeal considers balancing act between

06.12.2023

On 17 November 2023, the Competition and Markets Authority (CMA) published guidance offering reassurance that collaborations between medicine manufactures to make combination therapies available on the NHS will not face competition law challenge, provided certain conditions are fulfilled.
The guidance, which comes in the form of a ‘Prioritisation statement on combination therapies’ has